BACKGROUND: Mutations in the cardiac beta myosin heavy chain gene causing hypertrophic cardiomyopathy have been identified, and to assist both diagnosis and prediction of outcome attempts have been made to correlate phenotype and genotype. Two new mutations in codon 403 of the gene in three unrelated families are described and attention drawn to variable or even absent phenotypic expression in different family members. METHODS AND RESULTS: The polymerase chain reaction and heteroduplex analysis on Mutation Detection Enhancement gels were used to search for mutations in the globular head of the beta myosin heavy chain gene in families with hypertrophic cardiomyopathy. Two mutations were found in exon 13 (codon 403) of the gene. In two unrelated Polish families the mutation resulted in the conversion of arginine to tryptophan (CGG: >TGG). A second mutation, found in a British family, converted the same arginine to leucine (CGG: >CTG). These mutations were detected in family members who had electrocardiographic and echocardiographic features typical of hypertrophic cardiomyopathy; however, they were also detected in 7 other adult relatives with an abnormal electrocardiogram but a normal echocardiogram. Two unrelated adult relatives had completely normal clinical findings but carried the gene mutation. CONCLUSIONS: Identification of a specific mutation gives no guide to the clinical phenotype. There is considerable variability in the phenotypic expression of hypertrophic cardiomyopathy. Mutations were detected in adults previously regarded as normal or in whom the diagnosis was questionable. The fact that the clinical significance of the mutation in these people is still unknown emphasises the dilemma facing screening programmes. Isolated, unexplained electrocardiographic abnormalities in first degree relatives in a family with a definitive diagnosis of hypertrophic cardiomyopathy should be regarded as evidence of a carrier state.
BACKGROUND: Mutations in the cardiac beta myosin heavy chain gene causing hypertrophic cardiomyopathy have been identified, and to assist both diagnosis and prediction of outcome attempts have been made to correlate phenotype and genotype. Two new mutations in codon 403 of the gene in three unrelated families are described and attention drawn to variable or even absent phenotypic expression in different family members. METHODS AND RESULTS: The polymerase chain reaction and heteroduplex analysis on Mutation Detection Enhancement gels were used to search for mutations in the globular head of the beta myosin heavy chain gene in families with hypertrophic cardiomyopathy. Two mutations were found in exon 13 (codon 403) of the gene. In two unrelated Polish families the mutation resulted in the conversion of arginine to tryptophan (CGG: >TGG). A second mutation, found in a British family, converted the same arginine to leucine (CGG: >CTG). These mutations were detected in family members who had electrocardiographic and echocardiographic features typical of hypertrophic cardiomyopathy; however, they were also detected in 7 other adult relatives with an abnormal electrocardiogram but a normal echocardiogram. Two unrelated adult relatives had completely normal clinical findings but carried the gene mutation. CONCLUSIONS: Identification of a specific mutation gives no guide to the clinical phenotype. There is considerable variability in the phenotypic expression of hypertrophic cardiomyopathy. Mutations were detected in adults previously regarded as normal or in whom the diagnosis was questionable. The fact that the clinical significance of the mutation in these people is still unknown emphasises the dilemma facing screening programmes. Isolated, unexplained electrocardiographic abnormalities in first degree relatives in a family with a definitive diagnosis of hypertrophic cardiomyopathy should be regarded as evidence of a carrier state.
Authors: J A Jarcho; W McKenna; J A Pare; S D Solomon; R F Holcombe; S Dickie; T Levi; H Donis-Keller; J G Seidman; C E Seidman Journal: N Engl J Med Date: 1989-11-16 Impact factor: 91.245
Authors: A A Geisterfer-Lowrance; S Kass; G Tanigawa; H P Vosberg; W McKenna; C E Seidman; J G Seidman Journal: Cell Date: 1990-09-07 Impact factor: 41.582
Authors: C C Liew; M J Sole; K Yamauchi-Takihara; B Kellam; D H Anderson; L P Lin; J C Liew Journal: Nucleic Acids Res Date: 1990-06-25 Impact factor: 16.971
Authors: Carlos Alberto Pastore; Nelson Samesima; Horácio Gomes Pereira Filho; Leonardo Paschoal Camacho Varoni; Carlos Eduardo Rochitte; Marcelo Luiz Vieira; Luiz Francisco Rodrigues de Ávila; Rodrigo de Jesus Louzeiro Melo; Alexandre da Costa Pereira; Julia Daheer; Carlos Henrique del Carlo Journal: Ann Noninvasive Electrocardiol Date: 2014-11-04 Impact factor: 1.468
Authors: Neal K Lakdawala; Jens Jakob Thune; Barry J Maron; Allison L Cirino; Ole Havndrup; Henning Bundgaard; Michael Christiansen; Christian M Carlsen; Jean-François Dorval; Raymond Y Kwong; Steven D Colan; Lars V Køber; Carolyn Y Ho Journal: Am J Cardiol Date: 2011-09-21 Impact factor: 2.778
Authors: J C Moon; J Mogensen; P M Elliott; G C Smith; A G Elkington; S K Prasad; D J Pennell; W J McKenna Journal: Heart Date: 2005-08 Impact factor: 5.994
Authors: Andrés Ricardo Pérez-Riera; Augusto Armando de Lucca; Raimundo Barbosa-Barros; Frank G Yanowitz; Silvia Fortunato de Cano; Manuel Nicolás Cano; Antônio Carlos Palandri-Chagas Journal: Ann Noninvasive Electrocardiol Date: 2013-07 Impact factor: 1.468